LupiximAb 500 mg Injection (Rituximab) – Biotechnology Grade | Medicina Overseas

LupiximAb 500 mg Injection (Rituximab) is a biosimilar version of the monoclonal antibody targeting the CD20 antigen on B lymphocytes. It is widely used in oncology and immunology because of its strong efficacy and well-established safety profile.

Indications & Uses

LupiximAb is indicated for:

• Non-Hodgkin’s Lymphoma (NHL)

• Chronic Lymphocytic Leukemia (CLL)

• Rheumatoid Arthritis (in some treatment regimens)

• Granulomatosis with Polyangiitis (GPA) / Microscopic Polyangiitis (MPA)

• Other B-cell mediated disorders (as per regulatory approval by country)

Its versatility makes it one of the most in-demand monoclonal antibody therapies in both cancer and immune-dysfunction markets.

Mechanism of Action

Rituximab binds specifically to CD20, a protein expressed on the surface of B cells. This binding triggers immune-mediated B-cell destruction (via ADCC and complement-dependent cytotoxicity), reducing abnormal B-cell populations. This action helps in controlling cancerous B-cells in lymphoma and lymphocytic leukemia, and modulating pathological B-cell activity in autoimmune diseases. 

Formulation & Packaging

• Strength: 500 mg / 50 mL (10 mg/mL) 

• Vial type: Single-dose Type I clear glass vial with butyl rubber stopper

• Excipients: Polysorbate 80, sodium chloride, citrate buffer, water for injection 

Storage & Handling

• Store refrigerated at 2–8 °C, protect from light. 

• Do not freeze, do not shake vial.

• After dilution: the solution (1–4 mg/mL) in 0.9% sodium chloride or 5% dextrose can be stored up to 24 hours at 2–8 °C (and some formulations more, depending on the product). 

Why Choose Medicina Overseas for LupiximAb

• 100% genuine biosimilar sourced from Lupin Ltd

• Cold-chain export ensures drug stability and potency

• Full export documentation: COA, MSDS, packing list, temperature data

• Flexible MOQ for bulk or tender buyers

• Global shipping via trusted logistics partners

• Support for regulatory imports: we help with import license, clearance, and compliance

Administration & Dosage

LupiximAb must be administered by a qualified healthcare professional via IV infusion. Typical dilution: 1–4 mg/mL in infusion bag. 
Pre-medication (antihistamines, acetaminophen, steroids) is often required to minimize infusion reactions.
Monitor patients closely during the first infusion due to risk of infusion-related reactions.

Safety & Precautions

• Risk of infusion-related reactions, especially during the first dose.

• Risk of Hepatitis B reactivation in patients previously infected with HBV — screening recommended. 

• Progressive Multifocal Leukoencephalopathy (PML) risk: inform patients of risk and monitor. 

• Use with caution in immunocompromised patients.

Global Availability & Use Cases

Medicina Overseas exports LupiximAb to importers in various regions: Middle East, Africa, Southeast Asia, Latin America, and other markets. We cater to:

• Oncology hospitals & treatment centres

• National import tenders

• Specialty distributors

• Government & NGO buyers

Order Process

1. Submit an enquiry with quantity & destination

2. Share import license (if required)

3. Receive pro forma invoice (PI) with full cost + transit time

4. Process payment → Dispatch via cold-chain logistics

5. Receive supporting documents (COA, MSDS, temperature logs)